Our Vaccines business is one of the largest in the world, developing, producing and distributing over 2.5 million vaccines every day to people across 170 countries.

GSK vaccines continue to protect millions of people across the world from diseases that could otherwise be life-threatening. Our global vaccines portfolio includes products that help fight some of the most critical diseases like pneumococcal disease, meningitis, hepatitis, rotavirus, whooping cough, small pox and influenza. In the area of preventive healthcare, GSK Vaccines is the long-standing leader in the private vaccines market in India.

Our Marketplace

Vaccination is one of the most cost-effective and successful public health interventions. In 2012, the WHO and its 194 member states published an action plan on vaccination to extend access to immunisation to everyone in the world, promote innovation in the vaccines industry and prevent millions of deaths.

In India, more than 25 million children are born every year and it is estimated that by 2020 there will be more than a billion people in the world aged over 60. To meet this demand, it is crucial that we have a long-term sustainable business. We offer a range of vaccines for the prevention of hepatitis A, hepatitis B, invasive disease caused by H, influenzae, chickenpox, diphtheria, pertussis, tetanus, rotavirus, cervical cancer, and streptococcus pneumonia among others. In the pipeline are development of vaccines to cover many diseases that still have a serious impact around the world, including malaria, HIV, TB and Ebola.

Our Strategy

We believe that the protection from life-threatening diseases provides opportunities for greater health not just for individuals, but also for the communities in which they live. Yet, 22 million children in low-income and least-developed nations still don’t have access to any vaccines. To bridge the gap, we have a sustainable business approach in the way we develop, manufacture and distribute our vaccines.

Our strategy in India is to make our vaccines accessible to people in all communities, and in remote areas where building awareness is of fundamental importance. Our research and development team is working relentlessly towards finding new and improved vaccines that would ensure greater health for people in the years to come.

In fact, at GSK Vaccines, we do more than search for new ways to help prevent disease. As part of our commitment to improve patient education, we are also developing educational materials that medical professionals can use to help educate patients about vaccine-preventable diseases.

Quality and manufacturing

GSK is one of the world’s most innovative developers of vaccines. In 2012 we supplied 21% of the global vaccine market, in 2013, we distributed over 860 million doses of vaccines to 170 countries, and in 2014 we distributed more than 800 million doses of vaccine around the world. To meet the growing need for high quality vaccines in the future, we are investing in new manufacturing facilities and partnerships. In India, vaccines are currently labelled and packaged at our Nashik facility which has made significant progress specifically in Quality, EHS and Manufacturing.

Our manufacturing sites and processes adhere to the strictest regulations and guidelines and each of our vaccines is produced to the same quality standard, regardless of where in the world the vaccine will be used. We check quality throughout the production cycle, including our people, our manufacturing facilities, equipment used, and all components of all our vaccines. On an average, each batch of vaccine will have undergone more than 100 quality checks before it is sent out, to ensure the vaccines meet world-class standards.

Research & Collaborations

At GSK, while we make the most of our own expertise, we also work in symbiotic partnerships and alliances to leverage the most of our collective abilities. We understand that we can achieve more through collaboration and we are partnering with research organisations, academic institutions, NGOs, governments and other manufacturers to improve access, encourage innovation, and to enhance the quality and efficacy of immunisation. For the least developed countries, we work closely with organisations such as Gavi, the Vaccine Alliance and UNICEF.

More than 90% of the vaccines in our pipeline are being developed in partnership with others and we maintain over 100 partnerships in R&D alone. We now have three global R&D hubs - at Rockville, USA; Rixensart, Belgium and Siena, Italy, which are focused on discovering and developing novel vaccines across a range of pressing public health threats. GSK is a dedicated contributor to the global initiative - Decade of Vaccines Collaboration and the Global Vaccine Action Plan.